Aligos Therapeutics (NASDAQ:ALGS) Announces Earnings Results, Beats Expectations By $0.08 EPS

Aligos Therapeutics (NASDAQ:ALGS) announced its earnings results on Thursday. The company reported ($2.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.29) by $0.08, FiscalAI reports. Aligos Therapeutics had a negative return on equity of 119.24% and a negative net margin of 1,919.68%.The business had revenue of $2.83 million during the quarter, compared to analyst estimates of $0.25 million.

Aligos Therapeutics Trading Up 6.8%

ALGS opened at $6.44 on Friday. The company has a fifty day moving average price of $7.10 and a two-hundred day moving average price of $8.16. Aligos Therapeutics has a 1-year low of $4.47 and a 1-year high of $13.69. The company has a market cap of $39.86 million, a P/E ratio of -0.74 and a beta of 2.28.

Institutional Trading of Aligos Therapeutics

Several large investors have recently made changes to their positions in ALGS. Susquehanna International Group LLP acquired a new position in Aligos Therapeutics during the 3rd quarter worth approximately $99,000. XTX Topco Ltd bought a new position in Aligos Therapeutics in the second quarter worth approximately $100,000. HRT Financial LP acquired a new stake in Aligos Therapeutics in the fourth quarter valued at approximately $106,000. DRW Securities LLC acquired a new stake in Aligos Therapeutics in the fourth quarter valued at approximately $111,000. Finally, Jane Street Group LLC bought a new stake in shares of Aligos Therapeutics during the fourth quarter valued at approximately $226,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ALGS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aligos Therapeutics in a report on Monday, April 20th. Jefferies Financial Group upgraded shares of Aligos Therapeutics to a “strong-buy” rating in a report on Thursday, March 26th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Aligos Therapeutics in a research report on Wednesday, March 11th. Wall Street Zen lowered shares of Aligos Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, Westpark Capital started coverage on shares of Aligos Therapeutics in a research report on Thursday, March 26th. They set a “buy” rating and a $48.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.50.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.